BIP! Finder - Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia, Focusing on Long Term Cytopenias Before and After the Era of Targeted Therapies

2021 • Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia, Focusing on Long Term Cytopenias Before and After the Era of Targeted Therapies

Authors: Róbert Szász, Béla Telek, Árpád Illés

Venue: Pathology and Oncology Research

Type: Article

Abstract: The widespread application of fludarabine, cyclophosphamide, and rituximab combination is limited due to its toxicity, particularly the prolonged cytopenias. The study aimed to compare the prolonged cytopenias depending on fitness and report real-life data on dose reduction measures and efficacy. According to our database, 120 and 14 patients were treated with FCR between 2011 and 2015 and between 2016 and 2019. Out of the first cohort, 34 patients were treated in subsequent lines. The complete and partial remission rate after first-line treatm... (read more)

Topics: Internal medicine Oncology Immunology

DOI: 10.3389/pore.2021.1609742

BIP! social metrics: 0 4
External links: Crossref , OpenAIRE

References (24) Citations (1) BibTex PDF

Overall Ranking

Ranking within Venue

Impact aspects and other metrics

Popularity: This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
Influence: This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
Citation Count: This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
Impulse: This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.